Cytotoxic T lymphocytes (CTL) reactive with human mela noma tumor cells occasionally display cross-reactivity with normal melanocytes. Previously, we identified the melanocyte lineage-specific antigen gp 100 that is expressed by both mela noma cells and normal melanocytes, as a target antigen for tumor-infiltrating lymphocytes derived from a melanoma pa tient (TIL 1200). Here, we demonstrate that the oligoclonal HLA-A2.1-restricted TIL 1200 line is reactive with 2 distinct peptides derived from the gplOO protein. Apart from the peptide corresponding to gplOO amino acids 457-466, we identified the gplOO peptide E5 4 -162 as a second epitope recognized by TIL 1200. A 100-fold lower concentration of this novel gplOO peptide was required for target-cell sensitization compared to peptide 457-466, indicating that the 154-162 peptide is the dominant gplOO epitope for TIL 1200. Together with the recently described gplOO 280-288 epitope, 3 distinct CTL epitopes have now been identified in gplOO, all presented in the context of HLA-A2.1. Therefore, gplOO is an attractive target antigen in the development of immuno-therapeutic protocols against melanoma. 3To whom correspondence and reprint requests should be sent, at
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CTL that recognize melanoma tumor cells in a T-cellreceptor (TcR)-mediated and MHC-restricted manner have been isolated from tumor-bearing patients (for a review see Knuth et al, 1992). However, the identity of the antigens and epitopes recognized by anti-melanoma CTL remains largely unknown. These CTL often display cross-reactivity with alloge neic HLA-A2.1 matched melanomas, implying that shared melanoma antigens are recognized in the context of HLA-A2.1 (Darrow et ai, 1989; Kawakami et al, 1992) , Recently, it has been reported that some CTL react not only with melanoma tumor cells but also with normal melanocytes, suggesting recognition of melanocyte differentiation antigens (Anichini et al, 1993) .
Using a genetic approach, Boon and colleagues have suc ceeded in identifying a number of antigens recognized by anti-melanoma CTL. Apart from the tumor-specific MAGE-1 and -3 antigens (Van der Bruggen et al, 1991; Gaugler et al, 1994) , they also identified the melanocyte lineage-specific tyrosinase protein as a target for melanoma-specific CTL (Brichard et al, 1993) . Similarly, we have identified the gplOO melanocyte-specific protein as a target antigen for melanoma tumor-infiltrating lymphocytes (TIL) (Bakker et al, 1994) . Recently, another melanocyte differentiation antigen, Melan A/MART-1, was identified as a target for anti-melanoma CTL (Coulieetal, 1994; Kawakami et al, 1994a) . Collectively, these findings demonstrate that melanocyte differentiation antigens can be immunogenic.
The gplOO antigen is an intracellular glycoprotein of approxi mately 100 kDa and is recognized by MAb NKI-beteb (Vennegoor et al, 1988) . Expression of gplOO is restricted to cells of the melanocytic lineage. Recently, we isolated a cDNA clone encoding gplOO (Adema et al, 1993). Characterization of the gplOO cDNA revealed that gplOO is a type-I transmembrane glycoprotein highly homologous to another melanocyte-specific protein, Pmell7 (Adema et al, 1994) . Introduction of the gplOO encoding cDNA into gp 100-negative BLM cells conferred susceptibility to lysis by tumor-infiltrating lympho cytes derived from a melanoma patient (TIL 1200) (Bakker et al, 1994) . Furthermore, short-term cultures of HLA-A2.1+ normal melanocytes were also Iysed by TIL 1200, demonstrat ing that TIL 1200 recognizes the non-mutated gplOO protein.
Recently, it has been demonstrated that a naturally pro cessed gplOO peptide (amino acids 280-288) that was identi fied by tandem mass spectroscopy, could direct target-cell lysis by HLA-A2.1+ restricted anti-melanoma CTL lines (Cox et al, 1994) . We have shown that TIL 1200 is reactive with the gplOO peptide 457-466 in the context of HLA-A2.1 (Kawakami et al, 1994b) . Here, we report the identification of a novel HLA-A2.1presented gplOO peptide, corresponding to amino acids 154-162, as the dominant epitope recognized by the oligoclonal TIL 1200 line.
Cell culture
TIL 1200 lymphocytes were isolated from metastatic mela noma and were grown as was described previously (Kawakami et a lj 1992). HLA-A2.1+ melanoma lines BLM and BLM gplOO H2.3 were cultured as described previously (Bakker et al, 1994) , COS-7 cells were grown in DMEM (GIBCO, Paisley, UK) supplemented with 7.5% FCS. TAP-deficient TxB cell hybrid T2 cells (Salter et al, 1985) were maintained in Iscove's medium (GIBCO) +1.5% FCS.
Peptides
Peptides were synthesized with a free carboxy-terminus either by f-moc peptide chemistry using an ABIMED Multiple Synthesizer 422 (Abimed, Langenfeld, Germany) or by t-boc chemistry on a Biosearch 9500 peptide synthesizer (New Brunswick, San Rafael, CA). Peptides were dissolved in DMSO and stored at -20°C.
DNA constmction and transfection
Isolation of the gplOO cDNA clone cl has been described elsewhere (Adema etal, 1993) . The gplOO cDNA was inserted into expression vectors pBJlneo (Lin et al, 1990), pCMVneo (Baker et al, 1990) and pSVL (Pharmacia, Woerden, The Netherlands). To generate a gplOO cDNA lacking the coding sequences for the peptide 457-466, PCR reactions were performed with the following combinations of oligonucleo-98 BÀKKER ET AL. tides: 5'-CATGGAAGTGACTGTCTACC-3' /5 '-CTGAGC-GAATTCGGAACCTGTAATACTTTCCG-3' and 5'-CT-G A G CG A A TTCG TG A A G AG ACAAGTCCCCC-3' 15' -TCACAGCATCATATGAGAGTAC-3' using the full-length gplOO cDNA as a template. PCR products were digested with Eco RI, ligated and served as a template for a nested PCR using the following primers: 5'-GCACAGGCCAACTGCAGA-3V5r-TTC AGTATCTGGTGCAGAAC-3'. The Kpn I-Cla I fragment from this PCR product was then replaced by the corresponding fragment in pCMVgplOOneo to generate pCMVgpl00DEL454-481neo. GplOO cDNA mutants DEL149-661 and DEL454-661 were obtained by deletion of the 1.7-kb Hind III and the 0.8-kb Eco RI fragments from pBJlgpl00DEL454-481neo respectively. GplOO cDNA mu tants DEL100-661, DEL194-528 and DEL167-508 were ob tained by deletion of the Bgl I-Sac I, Bam HI-Bgl II and Apa I-Nsi I fragments from pSVLgplOO respectively.
BLM ceils were transfected with 20 (jug of pCMV-gpl00DEL454-481neo DNA according to the calcium phos phate co-precipitation procedure (Graham and van der Eb, 1973) using calcium phosphate transfection systems (BRL, Gaithersburg, MD) and were selected with 1 mg/ml G418 (GIBCO). COS-7 cells were co-transfected with 5 \xg of pBJlHLA-A2.1neo and 5 |xg of pBJl or pSVL plasmids containing either full-length or deleted gplOO cDNAs using the DEAE-dextran/ chloroquine method (Seed and Aruffo, 1987) (the HLA-A2/1 cDNA was kindly provided by J.J. Neefjes, The Netherlands Cancer Institute, Division of Biochemistry, Amsterdam, The Netherlands). After 48 hr of transfection, COS-7 cells were used as stimulator cells in IFN7 release experiments,
Chromium-release assay
Chromium-release assays were performed as described pre viously (Bakker et al, 1994) , Briefly, 106 target cells were incubated with 100 jxCi Na^QCU (Amersham, Aylesbury, UK) for 1 hr. Various amounts of effector cells were then added to 2 x 103 target cells in triplicate wells of U-bottomed microtiter plates (Costar, Badhoevedorp, The Netherlands) in a final volume of 150 jil. In peptide recognition assays, target cells were pre-incubated with various amounts of peptide for 90 min at 37°C in a volume of 50 |xl prior to the addition of effector cells. After 5 hr of incubation, part of the supernatant was harvested and its radioactive content was measured.
conjugated GAM-IgG-F(ab') 2 (Zymed, San Francisco, CA) was used for the second incubation.
IFNy-release assay
TIL 1200 responder cells (105) were incubated together with 5 x 104 transiently transfected COS-7 stimulator cells in 300 |xl medium in the presence of 100 U/ml IL-2 in a flat-bottomed 96-well microtiter plate. After 24 hr of incubation, 100 |±1 of supernatant were harvested and screened for the presence of IFN7 using an hlFNy-IRMA immunoradiometric assay kit (Medgenix, Fleurus, Belgium).
HLA-A2.1 stabilization on T2 ceils
Peptide-induced HLA-A2.1 stabilization on T2 cells was performed as described previously (Nijman et al, 1993) . Briefly, peptides were diluted from DMSO stocks to 50,25 and 12.5 |xg/ml (final DMSO concentration 0.5%) and incubated together with 105 T2 cells for 14 hr at 37°C, 5% C 0 2 in serum-free Iscove's medium in a volume of 100 |xl in the presence of 3 [xg/ml human p2-microglobulin (Sigma, St Louis, MO). Stabilization of HLA-A2.1 molecules at the surface of T2 cells was analyzed by flow cytometry using a FACScan flow cytometer (Becton Dickinson, Mountain View, CA). Anti-HLA-A2 MAb BB7.2 (culture supernatant) (Parham and Brodsky, 1981) was used as a primary reagent. FITC-
RESULTS

TIL 1200 is reactive with more than one peptide derived from gplOO
To determine the nominal gplOO epitope being recognized by TIL 1200, a number of gp 100-derived peptides were synthesized according to the HLA-A2.1 binding motifs (Falk et al, 1991; Hunt et al, 1992; Ruppert et al, 1993) and tested for their ability to sensitize target cells (Kawakami et al, 19946) . Only one of these peptides, corresponding to amino acids 457-466, was able to induce target-cell lysis by TIL 1200. However, when this peptide was used in chromium-release assays (Fig. 1) , we observed only a low percentage of specific release (20-25%), Furthermore, a relatively high concentra tion of peptide (~ 1 0 0 ng/ml) was needed to induce target-cell lysis by TIL 1200. We therefore questioned whether other gplOO-derived peptides could be recognized by TIL 1200, a TIL line that was found to be oligoclonal when analyzed at the T-cell receptor (TcR) level (Shilyanski et al, 1994) .
A putative second gplOO peptide which was a candidate for recognition by TIL 1200, was peptide 280-288. This naturally processed peptide was identified using tandem mass spectros copy and found to be recognized with high affinity by 5 melanoma-specific CTL lines (Cox et al, 1994) . We tested this peptide for recognition by TIL 1200 but did not observe any reactivity (data not shown).
To address the question whether TIL 1200 might recognize another peptide derived from gplOO, we constructed a mutant gplOO cDNA. The resulting construct, pBJl-gpl00DEL454-481neo, encodes a protein in which the 457-466 peptide is absent. We transfected human HLA-A2.1 + gplOO-BLM melanoma cells with pBJl-gpl00DEL454-481neo DNA. Subse quently, G418-resistant BLM gplOO DEL454-4S1 clones were screened for expression of mutated gplOO using MAb NKIbeteb and tested in chromium-release assays using TIL 1200. As shown in Figure 2 , elimination of the 457-466 epitope did peptide concentration ([¿g/ml) F i g u r e 1 -TIL 1200 recognizes the gplOO 457-466 peptide. Chromium-labelled T2 target cells were pre-incubated for 90 min with various amounts of peptide. TIL 1200 lymphocytes were added at an effector to target ratio of 30:1. After 5 hr of incubation, chromium release was measured. Peptide 96-105 is an irrelevant gplOO-derived peptide that binds to HLA-A2. not abolish TIL 1200 reactivity: BLM gplOO DEL454-481 clones were efficiently lysed. We therefore conclude that the TIL 1200 line recognizes more than one epitope derived from gplOO.
GplOO peptide 154-162 is the second gplOO epitope recognized by TIL 1200
Subsequently, to define the region of the gplOO protein that contains the unknown second epitope, a number of different gplOO cDNA deletion mutants were generated that all lacked the sequence encoding the 457-466 epitope (Fig. 3) . These mutant gplOO cDNAs, cloned into the expression vectors pBJl-neo or pSVL, were transfected into COS-7 cells together with an expression vector carrying the HLA-A2.1 cDNA. These COS-7 transfectants were then tested for their ability to induce IFN7 secretion by TIL 1200 upon TcR engagement.
As shown in Figure 3 , TIL 1200 specifically secreted IFNy when stimulated with COS-7 cells transfected with HLA-A2.1 and the full-length gplOO cDNA. In accordance with the cytotoxicity data (Fig. 2) , we again observed TIL 1200 reactiv ity against the gplOO DEL454-481 mutant that does not encode the 457-466 epitope. From the other gplOO deletion mutants, only the DEL100-661 and DEL149-661 constructs were not recognized, thereby excluding the possibility that TIL 1200 was reactive with a peptide located N-terminal from amino-acid position 148 in the gplOO protein. We could also exclude the C-terminal region of the gplOO protein, because we observed TIL 1200 reactivity using a mutant construct, DEL454-661, encoding the first 453 amino acids of gplOO. The observation that a construct encoding the N-terminal region up to amino acid 166 was able to stimulate TIL 1200 (DELI 67-508), demonstrated that a presumptive second epitope was localized between amino acids 148-166 of the gplOO protein.
Several motifs have been described for 9-mer to 10-mer peptides binding to HLA-A2.1, that were deduced from naturally processed and synthetic HLA-A2.1 binding peptides (Falk et al, 1991; Hunt et al, 1992; Ruppert et al, 1993) . When these motifs were applied to the 148-166 region of the gplOO protein, no putative HLA-A2.1-binding peptides were found.
We therefore screened the 148-166 region of the gplOO protein for peptides that fitted into a less strict motif, including threonine residues at position 2. Using such a motif, a number of potential HLA-A2.1 binding peptides from the gplOO 148-166 region were synthesized. These peptides were loaded onto HLA-A2.1+ T2 cells and tested for their ability to induce TIL-1200-mediated target-cell lysis (Fig. 4 ). The 5 peptides tested were all able to sensitize T2 cells for lysis by TIL 1200 when applied at a concentration of 10 p-g/ml. All these peptides contain the 8 -mer peptide TWGQYWQV, corre sponding to gplOO amino acids 155-162. Next, all peptides were titrated to evaluate their relative ability to sensitize T2 target cells for lysis by TIL 1200. Figure 4 shows that the 9-mer peptide KTWGQYWQV elicited 50% of maximal specific lysis by TIL 1200 when applied at a concentration of 3 ng/ml, whereas the other peptides had to be applied at higher concentrations. Therefore, the 9-mer 154-162 peptide is most likely the naturally processed second gplOO epitope that is recognized by TIL 1 2 0 0 .
Binding of gplOO epitopes 154-162} 280-288 and 457-466 to HLA-A2.1
We compared the gplOO 155-162 and 457-466 epitopes, that are recognized by TIL 1200, to the above-mentioned gplOO 280-288 peptide and 2 known viral epitopes presented in HLA-A2.1: the influenza matrix 58-66 peptide (Gotch et al, 1987) and the HIV polymerase 510-518 peptide (Tsomides et  al., 1991) . We analyzed the HLA-A2.1 binding capacity of the different gplOO epitopes by means of an indirect binding assay using the processing-defective cell line T2 (Nijman et al,  1993) , With this assay, we observed similar HLA-A2.1 stabili zation with the gplOO 280-288 epitope and the tested viral epitopes (Fig. 5 ). Both the 154-162 and 457-466 gplOO epitopes bind to HLA-A2.1 with a low affinity compared to the gplOO 280-288 eptiope and the viral epitopes, From these data we conclude that the gplOO epitopes bind to HLA-A2.1 with distinct affinities.
DISCUSSION
In the present report, we describe the identification of a novel gplOO epitope, corresponding to gplOO amino acids 154-162, that is presented to anti-melanoma CTL in the context of HLA-A2.1. We show that the gplOO-reactive TIL 1200 line, consisting of several TcR specificities (Shilyanski et  al, 1994) , recognizes not only the gplOO 457-466 epitope, but also the gplOO 154-162 epitope. HLA-A2.1 binding experi ments revealed that the gplOO 154-162 epitope and the gplOO 457-466 epitope bind with relatively low affinity to HLA-A2.1, compared to the recently reported gplOO 280-288 epitope (Cox et al, 1994) and HLA-A2.1 restricted viral epitopes. This may be partly explained by the amino-acid composition of the gplOO epitopes recognized by TIL 1200. The lower affinity for HLA-A2.1 of peptide 457-466 may be due to the charged residues at positions 3 and 9 (Ruppert et al, 1993) . Inefficient binding of the gplOO 154-162 epitope to HLA-A2.1 may be caused by the presence of a threonine residue at the Nterminal anchor position since, in most HLA-A2.1 binding peptides, leucine or methionine residues are present at this site. While both peptides bind to HLA-A2.1 with low affinity, a 100-fold lower concentration of gplOO peptide 154-162 was required for the sensitization of T2 target cells for lysis by TIL 1200, when compared to gplOO peptide 457-466. We therefore consider the 154-162 peptide to be the dominant gplOO epitope recognized by TIL 1200. Attempts to further investi gate the recognition of the different gplOO epitopes using gp100 cDNA constructs IFNy (pg/ml) F i g u r e 3 -TIL 1 2 0 0 recognizes a second gplOO-derived epitope located between amino acids !49 and 1 6 6 . GplOO cDNA deletion mutants encoding parts of the gplOO protein were cloned into expression vectors and transfected into COS-7 along with the HLA-A2.1 cDNA (numbers indicate amino acids in the gplOQ protein, amino acid 1 refers to the methionine in the signal peptide). TIL 1 2 0 0 lymphocytes and transfected COS-7 cells were co-incubated for 24 hr and the amount of IFN7 in the supernatant was measured using an immunoradiometric assay. Figure 1 . Five peptides derived from the gplOO 148-166 region, varying from an 8-mer to an 11-mer, were tested for recognition by TIL 1200. T2 target cells were pre-incubated with various concen trations of peptide and specific lysis was determined at an effector to target ratio of 30:1. Peptides: VWKTWGQYWQV, ■ -■; KTWGQYWQVL, KTWGQYWQV, TWGQY-WQVL, 0 -0 ; TWGQYWQV, A-A, cloned TIL have not been successful. Since other anti-gplOO CTL-lines (Cox at ai, 1994) recognize the gplOO 280-288 epitope, it remains to be established which epitope is immuno dominant in gplOO.
It is surprising that, in a single patient, anti-melanoma CTL have emerged that are reactive with 2 distinct epitopes derived from gplOO, a self antigen. The gplOO epitopes are recognized by at least 2 T-cell specificities, co-existing within the TIL 1200 line, that display differences in TcR affinity. T lymphocytes bearing potential self-rcactive TcR can emerge in the periph ery. They may have escaped from tolerance induction because they bear low-affinity TcR, whereas potential autoreactive CTL bearing high-affinity TcR are probably deleted in the thymus (Schwartz, 1989) or maybe tolerized in the periphery. The anti-tyrosinase CTL clones described by Wôlfel and colleagues and the gplOO 457-466-reactive TIL 1200 lympho cytes, exhibiting low peptide/MHC affinity, may have emerged from precursor T lymphocytes of this type. High-affinity autoreactive CTL may have escaped tolerance induction, because they have not encountered their antigenic peptide in the thymus or in the periphery. It is not clear how high-or intermediate-affinity CTL, like gplOO 280-288-reactive T lym phocytes (C o x e t a l 1994) or gplOO 154-162-reactive TIL 1200 ymphocytes, can exist in the periphery as ignorant T lympho cytes without causing apparent autoimmune disease (Ohashi, 1994) . A possible explanation is that HLA-A2.1-gpIOO 154-162/ 280-288 complexes on normal melanocytes may be recognized by activated CTL, while being incapable of initiating primary immune responses in vivo. Apparently, in the case of mela noma, gplOO-reactive precursor T lymphocytes can be trig gered in vivo. This may be the result of a higher expression level of the gplOO antigen in melanoma cells. Alternatively, necrosis in melanoma tumors may lead to uptake and presenta tion of gplOO-derived peptides to T lymphocytes by profes sional antigen-presenting cells.
Clinical data, indicating that vitiligo (local depigmentation of the skin) is associated with improved survival of melanoma patients (Bystryn et al, 1987) , suggest that these patients benefit from an autoimmune response to melanocytes. In addition, re-infusion of TIL 1200 plus IL-2 into the autologous patient was accompanied by regression of metastatic tumor (Kawakami et a l, 19946) . This suggests that the generation of an immune response against the gplOO melanocyte differentia tion antigen may have anti-tumor effects in vivo. Therefore, the gplOO antigen, of which 3 distinct HLA-A2.1 presentable epitopes have already been identified, is an attractive target antigen in the development of immuno-therapeutic protocols against melanoma.
